人类细小病毒B19与血液制品的风险控制  

Safety control of human parvovirus B19 and blood/blood products

作　　者：刘彬[1] 魏琼书 马莉[1] 李长清[1] LIU Bin;WEI Qiongshu;MA Li;LI Changqing(Institute of Blood Transfusion,Chinese Academy of Medical Sciences&Peking Union Medical College,Chengdu 610052,China)

机构地区：[1]中国医学科学院北京协和医学院输血研究所,成都610052

出　　处：《中国药品标准》2022年第2期152-155,共4页Drug Standards of China

基　　金：国家药典委员会药品标准制修订研究课题资助项目(2019S01,2020S04)。

摘　　要：本文系统分析了人类细小病毒B19的特征及其对血液制品安全性的影响,以及国外对B19的风险控制策略。为建立我国相关技术要求和指南,保障血液/血液制品的病毒安全提供一定的参考。Characterization of human parvovirus B19 and its effects on the safety of blood/blood products were systemically analyzed,and foreign safety control strategies of human parvovirus B19 were described.It provides a valuable reference for the establishment of relevant standards and guidelines in China,which ensures the viral safety of blood/blood products.

关 键 词：人类细小病毒B19 血液/血液制品 安全性 筛查 

分 类 号：R921.2[医药卫生—药学]